Cargando…

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol

Chemotherapy related toxicities have been the major factor limiting the success of acute lymphoblastic leukemia (ALL) induction therapy. Several factors, including the pharmacogenetics of asparaginase and anthracyclines, could contribute to difference in treatment outcome in ALL. We investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aslam, Sara, Ameer, Sonia, Shabana, N. A., Ahmed, Mehboob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660848/ https://www.ncbi.nlm.nih.gov/pubmed/34887513 http://dx.doi.org/10.1038/s41598-021-03208-9

Ejemplares similares

Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
por: Jenkinson, S, et al.
Publicado: (2016)

Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial
por: Schwab, Claire, et al.
Publicado: (2022)

Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol‐E. coli L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials
por: Sidhu, Jasmeet, et al.
Publicado: (2022)

Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials
por: Enshaei, Amir, et al.
Publicado: (2021)

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
por: Patel, B, et al.
Publicado: (2017)

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials
por: Creasey, Thomas, et al.
Publicado: (2021)

Implications of ACMG guidelines to identify high-risk acute lymphoblastic leukemia patients with hereditary cancer susceptibility syndromes (HCSS) in a highly consanguineous population
por: Aslam, Sara, et al.
Publicado: (2021)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia
por: Cao, Minyuan, et al.
Publicado: (2020)

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2023)

Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population
por: de Carvalho, Darlen Cardoso, et al.
Publicado: (2020)

Pharmacogenetics of the Central Nervous System—Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia
por: Sági, Judit C., et al.
Publicado: (2021)

The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI
por: Halsey, Christina, et al.
Publicado: (2011)

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia
por: Maamari, Dimitri, et al.
Publicado: (2020)

Pharmacogenetic testing for thiopurine drugs in Brazilian acute lymphoblastic leukemia patients
por: Suarez-Kurtz, Guilherme, et al.
Publicado: (2023)

Compliance with a protocol for acute lymphoblastic leukemia in childhood
por: de Oliveira, Benigna Maria, et al.
Publicado: (2011)

Interactions of Consanguinity and Number of Siblings with Childhood Acute Lymphoblastic Leukemia
por: Kakaje, Ameer, et al.
Publicado: (2020)

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study
por: Moorman, Anthony V., et al.
Publicado: (2021)

Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
por: Marks, David I, et al.
Publicado: (2022)

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia
por: Gervasini, Guillermo, et al.
Publicado: (2012)

Population Analysis of Pharmacogenetic Polymorphisms Related to Acute Lymphoblastic Leukemia Drug Treatment
por: Chiabai, Marcela A., et al.
Publicado: (2012)

Pharmacogenetics of MicroRNAs and MicroRNAs Biogenesis Machinery in Pediatric Acute Lymphoblastic Leukemia
por: López-López, Elixabet, et al.
Publicado: (2014)

HLA-DPβ1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial
por: Taylor, G M, et al.
Publicado: (2012)

The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia
por: O'Connor, David, et al.
Publicado: (2023)

Risk assessment of FLT3 and PAX5 variants in B-acute lymphoblastic leukemia: a case–control study in a Pakistani cohort
por: Khalid, Ammara, et al.
Publicado: (2019)

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics
por: Lennard, Lynne, et al.
Publicado: (2014)

Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia
por: Gregers, J, et al.
Publicado: (2015)

The Microbiome in Childhood Acute Lymphoblastic Leukemia
por: Oldenburg, Marina, et al.
Publicado: (2021)

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009)

Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy
por: Schmiegelow, Kjeld, et al.
Publicado: (2017)

Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia
por: Widjajanto, Pudjo H, et al.
Publicado: (2013)

Obesity in patients with acute lymphoblastic leukemia in childhood
por: Iughetti, Lorenzo, et al.
Publicado: (2012)

Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation
por: Kong, Seom Gim, et al.
Publicado: (2014)

Epigenetic Priming in Childhood Acute Lymphoblastic Leukemia
por: Raboso-Gallego, Javier, et al.
Publicado: (2019)

Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
por: Mogensen, Pernille Rudebeck, et al.
Publicado: (2020)

Synthesized evidence for childhood acute lymphoblastic leukemia
por: Onyije, Felix M., et al.
Publicado: (2023)

Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2018)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Cerebral microbleeds in adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation
por: Phillips, Nicholas S., et al.
Publicado: (2020)

Infections During Induction Therapy of Protocol CCLG-2008 in Childhood Acute Lymphoblastic Leukemia: A Single-center Experience with 256 Cases in China
por: Li, Si-Dan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tl79ns0qikc0vlsdeja2460fbr